Literature DB >> 2447400

Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers.

C Valenzuela1, C Delgado, J Tamargo.   

Abstract

The effects of 5-hydroxypropafenone (5-OH-P), the main metabolite of propafenone, were studied in guinea pig papillary muscles obtained from untreated animals and from animals pretreated with 5-OH-P, 3 mg/kg for 24 days. In untreated muscles perfused with 2.7 and 5.4 mM K+, 5-OH-P depressed action potential amplitude and Vmax, reduced the resting membrane potential, and prolonged the effective refractory period (ERP), but had no effect on the duration of the action potential (APD), recovery time (RT), or ERP/RT ratio. 5-OH-P also shifted the membrane responsiveness curve downward and to the left (i.e., in hyperpolarizing direction), prolonged the ERP/APD ratio, depressed the amplitude and Vmax, and shortened the duration of the slow action potentials induced by isoproterenol in K+-depolarized muscles. Pretreatment with 5-OH-P had no effect on phase 0 characteristics or resting membrane potential, but it shortened the APD, ERP, and RT and decreased the ERP/APD ratio. Further addition of 5-OH-P produced similar but more marked changes than in untreated muscles. In papillary muscles perfused with 10 mM K+, the depressant effects of 5-OH-P on phase 0 characteristics and ERP/APD ratio were potentiated. A slight lengthening of the APD was also observed. Because all these effects are similar to those previously described with propafenone, it is concluded that 5-OH-P is an active metabolite which exhibits class 1 antiarrhythmic effects and which may be responsible for some of the cardiodepressant and antiarrhythmic effects previously described for propafenone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447400     DOI: 10.1097/00005344-198711000-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Electrophysiological effects of E-3753, a new antiarrhythmic drug, in guinea-pig ventricular muscle.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

2.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

3.  Stereoselective electrophysiological effects of propafenone in Langendorff perfused guinea pig hearts.

Authors:  U Stark; G Stark; K Stoschitzky; E Pilger; S Nagl; W Lindner; H A Tritthart
Journal:  Basic Res Cardiol       Date:  1992 Jan-Feb       Impact factor: 17.165

Review 4.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

5.  Effects of propafenone on 45Ca movements and contractile responses in vascular smooth muscle.

Authors:  R Carrón; F Pérez-Vizcaino; E Delpón; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

6.  Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.

Authors:  A Capucci; G Boriani; B Marchesini; E Strocchi; L Tomasi; M Balducelli; L Frabetti; E Ambrosioni; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 7.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.